ANL 0.00 No Change ▼ 0.00 (NAN%)
ASC 0.00 Decreased By ▼ -13.22 (-100%)
ASL 0.00 Decreased By ▼ -17.53 (-100%)
BOP 0.00 Decreased By ▼ -8.65 (-100%)
BYCO 0.00 Decreased By ▼ -7.29 (-100%)
FCCL 0.00 Decreased By ▼ -19.10 (-100%)
FFBL 0.00 No Change ▼ 0.00 (NAN%)
FFL 0.00 No Change ▼ 0.00 (NAN%)
FNEL 0.00 No Change ▼ 0.00 (NAN%)
GGGL 0.00 No Change ▼ 0.00 (NAN%)
GGL 30.00 Increased By ▲ 2.11 (7.57%)
HUMNL 6.65 Decreased By ▼ -0.13 (-1.92%)
JSCL 0.00 Decreased By ▼ -19.25 (-100%)
KAPCO 0.00 Decreased By ▼ -27.25 (-100%)
KEL 0.00 Decreased By ▼ -3.34 (-100%)
MDTL 0.00 No Change ▼ 0.00 (NAN%)
MLCF 34.25 Increased By ▲ 34.25 (INF%)
NETSOL 0.00 No Change ▼ 0.00 (NAN%)
PACE 0.00 No Change ▼ 0.00 (NAN%)
PAEL 0.00 Decreased By ▼ -26.49 (-100%)
PIBTL 0.00 No Change ▼ 0.00 (NAN%)
POWER 0.00 No Change ▼ 0.00 (NAN%)
PRL 15.80 Increased By ▲ 15.80 (INF%)
PTC 0.00 No Change ▼ 0.00 (NAN%)
SILK 0.00 No Change ▼ 0.00 (NAN%)
SNGP 0.00 No Change ▼ 0.00 (NAN%)
TELE 0.00 No Change ▼ 0.00 (NAN%)
TRG 0.00 No Change ▼ 0.00 (NAN%)
UNITY 0.00 Decreased By ▼ -29.35 (-100%)
WTL 0.00 No Change ▼ 0.00 (NAN%)
BR100 4,411 Decreased By ▼ -322.03 (-6.8%)
BR30 20,247 Decreased By ▼ -92.41 (-0.45%)
KSE100 45,501 Decreased By ▼ -43.16 (-0.09%)
KSE30 17,806 Decreased By ▼ -4.7 (-0.03%)

Anglo Swedish drugmaker

AstraZeneca's lower EU vaccine supply target hinges on factory approval: document
Business & Finance

AstraZeneca's lower EU vaccine supply target hinges on factory approval: document

  • The Anglo-Swedish drugmaker said on Friday it would try to deliver 30 million doses to the EU by the end of March, down from a contractual obligation of 90 million and a previous pledge made last month to deliver 40 million doses.
  • AstraZeneca said in the document seen by Reuters that it is assuming the Halix factory will get the green light on March 25 and has pencilled in deliveries of nearly 10 million doses for the following week.
Updated 13 Mar, 2021 09:10pm
AstraZeneca/Oxford vaccine more effective with longer dose gap: study
Business & Finance

AstraZeneca/Oxford vaccine more effective with longer dose gap: study

  • The study confirmed the Anglo-Swedish drugmaker's findings from earlier this month that showed the vaccine had 76% efficacy against symptomatic coronavirus infection for three months after the first dose.
  • Efficacy was found to be at 81% with the longer interval of 12 weeks between the first and second dose, compared with 55% efficacy up to the six-week gap.
Published 19 Feb, 2021 09:17pm